EndoChoice receives "strong buy" rating from analysts: 4 points

EndoChoice stock has earned a "strong buy" rating from four analysts, according to a Storm Investor report.

Here are four points:

1. Analysts have set a 12-month consensus target price of $19.67 for the stock.

2. EndoChoice has a 12-month low of $7.37 and a 12-month high of $19.69.

3. The firm has a 50-day moving average of $8.92 and a 200-day moving average of $13.40.

4. The stock's market cap is $205.05 million.

More articles on GI/endoscopy:
Offering Cologuard increases colonoscopy at USMD Health System
Torax Medical's continence restoration system receives FDA clearance, Advanced Endoscopy Devices contracts with Premier & more – 4 GI/endoscopy company key notes
GI physician leader to know: Dr. Christine Carter-Kent of Medical University of South Carolina

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers